Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions: placebo, iv sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 0 Days to 4 Days
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 20
States / cities: Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more

Conditions: Metastatic Colorectal Carcinoma, Neuropathy
Interventions: BXQ-350, Placebo; Drug · Other
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 12
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 9 more

Conditions: Femoral Neck Fractures
Interventions: Tranexamic Acid, Placebo (saline); Drug
Lead sponsor: UConn Health; Other
Eligibility: 55 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Farmington, Connecticut • Hartford, Connecticut

Conditions: Obesity
Interventions: BTA, Placebo (normal saline); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiopulmonary Bypass, Inflammation, Fibrinolysis, Surgery
Interventions: HOE 140, Aminocaproic Acid, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Ovarian Cancer, Uterine Cancer
Interventions: fosaprepitant, aprepitant, Oral Placebo, IV placebo; Drug · Other
Lead sponsor: Gynecologic Oncology Associates; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Complex Obstetric Surgery, Perioperative Pain Management, Cesarean Delivery, Postoperative Pain Control
Interventions: Bupivicaine intervention arm, Placebo arm; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Vasoplegic Syndrome
Interventions: Hydroxocobalamin, Cardiopulmonary Bypass, Placebos; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hematologic Malignancies
Interventions: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review; Biological · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Diabetes
Interventions: Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Urinary Tract Infections
Interventions: Cystoscopic Fluid containing Neosporin G. U. Irrigant, Cystoscopy, Cystoscopic Fluid/Placebo; Drug · Procedure
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sepsis, Kidney Injury, Thiamine Deficiency
Interventions: Thiamine Hydrochloride, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Manhasset, New York • New York, New York + 1 more

Conditions: Healthy
Interventions: IXT-m200, Placebo; Drug · Other
Lead sponsor: InterveXion Therapeutics, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Parkinson's Disease, Essential Tremor, Dystonia
Interventions: Dexmedetomidine Hydrochloride Infusion, Normal Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Homocystinuria
Interventions: Pegtibatinase, Placebo; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more

Conditions: Post COVID-19 Syndrome
Interventions: HB-adMSCs (allogeneic), Placebo; Biological · Other
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Osteoporosis
Interventions: Zoledronic acid, Placebo, Teriparatide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years to 89 Years · Female only
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: CodaVax-RSV, Normal Saline; Biological
Lead sponsor: Codagenix, Inc; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab, Placebo to pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 20
States / cities: Anchorage, Alaska • Phoenix, Arizona • Orange, California + 15 more

Conditions: Pouch, Ileal, Fistula
Interventions: Ossium vBM-MSC, Placebo; Drug · Other
Lead sponsor: Anthony Lembo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Upper Airway Obstruction
Interventions: Physostigmine, Oxygen, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Osteopenia
Interventions: Zoledronic Acid, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Lung Transplant; Complications, Mechanical, Lung Transplant; Complications, Bleeding, Hemoptysis
Interventions: Topical epinephrine, Placebos; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Prematurity, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn
Interventions: Aerosolized Normal Saline, Inhaled PGE1; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 7 Days
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more

Search by objective public record fields.

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty

Effects of Gastric Antral Botulinum Toxin Injections in Obese Subjects

Bradykinin Receptor Antagonism During Cardiopulmonary Bypass

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

COMFORT Trial: Complex Obstetric Management With Focused Regional Transversus Abdominis Plane Block

Vitamin B12a Vasoplegic Syndrome

IVIG for Infection Prevention After CAR-T-Cell Therapy

Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus

Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection

Thiamine as a Renal Protective Agent in Septic Shock

Safety, Tolerability, and Pharmacokinetics of IXT-m200

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease

Phamacological Reversal of Airway Instability During Sedation

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies

Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)